Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Completed · Phase 2

Conditions studied: Hepatitis C Virus

In brief

This study is to evaluate the safety, tolerability, and antiviral activity of sofosbuvir (SOF) with ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.

Key facts

Study ID

NCT01713283

Run by

Gilead Sciences

People needed

60

Starts

2012-10-01

Expected to finish

2014-02-01

Last updated by the study team

2014-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• First generation Egyptian; must have been born in Egypt and can trace both maternal and paternal Egyptian ancestry
• Treatment-experienced or treatment-naive
• Chronic genotype 4 HCV infection
• Not co-infected with HIV
• Screening laboratory values within defined thresholds
• Use of highly effective contraception methods
• Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments

You may not qualify if…

• History of any other clinically significant chronic liver disease
• Pregnant or nursing female or male with pregnant female partner
• History of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol
• Excessive alcohol ingestion or significant drug abuse

Where it is running

• Study site — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.